search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


The effect of glycopyrroniumbromide on hypersalivation in patients with Parkinson's disease: a randomised, cross-over, doubleblind, placebocontrolled trial.


- candidate number2430
- NTR NumberNTR862
- ISRCTNISRCTN28592111
- Date ISRCTN created8-feb-2007
- date ISRCTN requested7-feb-2007
- Date Registered NTR24-jan-2007
- Secondary IDsAPOMST001 
- Public TitleThe effect of glycopyrroniumbromide on hypersalivation in patients with Parkinson's disease: a randomised, cross-over, doubleblind, placebocontrolled trial.
- Scientific TitleThe effect of glycopyrroniumbromide on hypersalivation in patients with Parkinson's disease: a randomised, cross-over, doubleblind, placebocontrolled trial.
- ACRONYMGlyspar study
- hypothesisThe aim of this study is to prove the efficacy of 3 times daily 1 mg glycopyrronium bromide admixture versus placebo admixture in patients with PD with hypersalivation. Furthermore, the safety of glycopyrronium bromide used in the mentioned dosage will be further evaluated. In addition, the aim is to perform a pharmacogenetic analysis with these data within the purpose of this study.
- Healt Condition(s) or Problem(s) studiedHypersalivation, Parkinson patient
- Inclusion criteria1. Patients with Parkinson's disease;
2. Age >=18 years;
3. Hypersalivation score >=5 (on a scale from 1-9);
4. Patient or family is able to score the extent of hypersalivation.
- Exclusion criteria1. Hypersensitivity to glycopyrronium bromide, sorbic acid or saccharin sodium;
2. Myasthenia gravis;
3. Symptomatic tachycardia;
4. Coronary insufficiency;
5. Heart rythm disorders;
6. Glaucoma;
7. Pylorus stenosis;
8. Paralytic ileus;
9. Prostate hypertrophy;
10 Patients using potassiumchloride tablets, oral digoxin or oral corticosteroids;
11. Kidney function disorders;
12. Pregnancy or lactation.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingTriple
- controlPlacebo
- groupCrossover
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-feb-2007
- planned closingdate1-jan-2009
- Target number of participants24
- InterventionsCross over design: In week 2 glycopyrroniumbromide (3 times 1mg=5ml daily) or placebo (3 times 5ml daily ). In week 4 cross-over glycopyrroniumbromide (3 times 1mg=5ml daily) or placebo (3 times 5ml daily).
- Primary outcomePercentage of patients with a decrease of 3 points on the hypersalivation score (on a scale from 1-9).
- Secondary outcomeThe difference in mean improvement on the hypersalivation score between the two groups. Furthermore, the difference in reported adverse events will be analysed.
- Timepoints
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESDr. P.J.E. Poels
- CONTACT for SCIENTIFIC QUERIES M.E.L. Arbouw
- Sponsor/Initiator Hospital Medisch Spectrum Twente, Department of clinical pharmacy
- Funding
(Source(s) of Monetary or Material Support)
Hospital Medisch Spectrum Twente, Department of clinical pharmacy
- PublicationsN/A
- Brief summaryThe aim of this study is to prove the efficacy of 3 times daily 1 mg glycopyrronium bromide versus placebo in patients with PD with hypersalivation. In week 1 there are baseline measurements, in week 2 glycopyrroniumbromide or placebo will be taken, in week 3 there are new baseline measurements, in week 4 cross-over glycopyrroniumbromide or placebo will be taken. The final visit will be in week 5. Patients score the extent of hypersalivation three times a day on a daily basis (scale from 1-9).
- Main changes (audit trail)
- RECORD24-jan-2007 - 28-nov-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl